Drug Trial Radar · NCT06451159
A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Jun 20, 2024
Primary completion
Feb 1, 2026
Study completion Feb 2027
Sponsor
- Lead sponsor
- Bruce CreeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Kyverna Therapeutics
- First posted
- Jun 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 25 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to test a drug called KYV-101 in people who have progressive multiple sclerosis (MS) and who have not responded to standard therapies to slow disease progression. The main questions it aims to answer are: * What is the highest therapy dose that can be given without causing harm? * Can this therapy enter the central nervous system? Participants will be asked to: * Attend 14 visits plus an 8-day inpatient hospital stay over the course of 58 weeks. * Complete apheresis and chemotherapy treatments in preparation for KVY-101 therapy. * Undergo medical and research testing such as physical and neurological exams, MRI, lumbar puncture, blood draws, questionnaires, and vision assessments.
Conditions
- Progressive Multiple Sclerosis
Interventions
KYV-101 (Biological) - 0.33 ×10^8 cellsBiological
KYV-101 is a type of treatment called CAR T-cell therapy. It uses cells from your own immune system, called T-cells, to attack cells that cause inflammation. T-cells are a type of white blood cell.
KYV-101 (Biological) - 1 ×10^8 cellsBiological
KYV-101 is a type of treatment called CAR T-cell therapy. It uses cells from your own immune system, called T-cells, to attack cells that cause inflammation. T-cells are a type of white blood cell.
Chemotherapy: cyclophosphamide (CYC)Drug
Participants will receive one 3-day cycle of lymphodepletion with CYC 300 mg/m2 prior to administration of KYV-101.
Chemotherapy: fludarabine (FLU)Drug
Participants will receive one 3-day cycle of lymphodepletion with FLU 30 mg/m2 prior to administration of KYV-101.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The presence of CAR-T cells in CSF following their peak expansion in peripheral blood.Time frame: Screening to Week 48
- The incidence and severity of adverse events and dose-limiting toxicities.Time frame: Screening to Week 48
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California, San Francisco, Multiple Sclerosis Center
San Francisco, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.